PMID- 36566807
OWN - NLM
STAT- MEDLINE
DCOM- 20230120
LR  - 20230120
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 228
DP  - 2023 Feb 15
TI  - Cancer immunotherapeutic effect of carboxymethylated beta-d-glucan coupled with iron 
      oxide nanoparticles via reprogramming tumor-associated macrophages.
PG  - 692-705
LID - S0141-8130(22)03061-6 [pii]
LID - 10.1016/j.ijbiomac.2022.12.154 [doi]
AB  - The cancer immunotherapeutic effect of a carboxymethylated beta-d-glucan 
      (CMPTR)/iron oxide nanoparticles (IONPs) system (CMPTR/IONPs) were investigated 
      by using cell culture of bone marrow-derived macrophages (BMDMs) and B16F10 
      melanoma skin cancer-bearing mouse model. When compared with that of control 
      group, CMPTR/IONPs-treated M2-like BMDMs exhibited upregulated M1 biomarkers 
      expression, significantly inhibited the migration of B16F10 cancer cells 
      (p < 0.05), and had the highest apoptotic percentage of B16F10 cancer cells 
      (80.39 +/- 8.73 %) in co-culture system. Intratumoral administration of CMPTR/IONPs 
      significantly (p < 0.05) suppressed tumor growth (46.58 % based on tumor weight) 
      in mice and enhanced the M1/M2 ratio from 0.40 +/- 0.09 (control group) to 
      6.64 +/- 1.61 in tumor associated macrophages (TAMs) which was higher than that of 
      in CMPTR (1.27 +/- 0.38), IONPs (1.38 +/- 0.17). CMPTR/IONPs treatment also promoted 
      apoptosis in cancer cells and increased the infiltration of CD4 and CD8 
      T-lymphocytes in tumor tissues. These results could be due to the combined 
      effects of CMPTR and IONPs in the CMPTR/IONPs system, possibly mediated by the 
      activation of NF-kappaB and IRF5 pathways for inducing M1 macrophages polarization 
      and had potential cancer immunotherapeutic applications.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Su, Yuting
AU  - Su Y
AD  - College of Civil and Transportation Engineering, Shenzhen University, Shenzhen 
      518060, China; Shenzhen Key Laboratory of Marine Microbiome Engineering, 
      Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China; 
      Institute for Innovative Development of Food Industry, Shenzhen University, 
      Shenzhen 518060, China; School of Life Sciences, The Chinese University of Hong 
      Kong, Shatin, New Territories, Hong Kong, China.
FAU - Yang, Fan
AU  - Yang F
AD  - School of Life Sciences, The Chinese University of Hong Kong, Shatin, New 
      Territories, Hong Kong, China.
FAU - Wang, Mingfu
AU  - Wang M
AD  - Shenzhen Key Laboratory of Marine Microbiome Engineering, Institute for Advanced 
      Study, Shenzhen University, Shenzhen 518060, China; Institute for Innovative 
      Development of Food Industry, Shenzhen University, Shenzhen 518060, China. 
      Electronic address: mfwang@szu.edu.cn.
FAU - Cheung, Peter C K
AU  - Cheung PCK
AD  - School of Life Sciences, The Chinese University of Hong Kong, Shatin, New 
      Territories, Hong Kong, China. Electronic address: petercheung@cuhk.edu.hk.
LA  - eng
PT  - Journal Article
DEP - 20221222
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Glucans)
RN  - 0 (Irf5 protein, mouse)
RN  - 0 (Interferon Regulatory Factors)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Tumor-Associated Macrophages/pathology
MH  - Glucans/therapeutic use
MH  - *Melanoma/drug therapy
MH  - Immunotherapy
MH  - Magnetic Iron Oxide Nanoparticles
MH  - *Nanoparticles
MH  - Interferon Regulatory Factors
OTO - NOTNLM
OT  - Cancer immunotherapeutic effect
OT  - Carboxymethylated beta-d-glucan
OT  - Iron oxide nanoparticles
OT  - Targeting delivery
OT  - Tumor-associated macrophages
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/12/26 06:00
MHDA- 2023/01/21 06:00
CRDT- 2022/12/25 19:12
PHST- 2022/09/14 00:00 [received]
PHST- 2022/11/28 00:00 [revised]
PHST- 2022/12/14 00:00 [accepted]
PHST- 2022/12/26 06:00 [pubmed]
PHST- 2023/01/21 06:00 [medline]
PHST- 2022/12/25 19:12 [entrez]
AID - S0141-8130(22)03061-6 [pii]
AID - 10.1016/j.ijbiomac.2022.12.154 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2023 Feb 15;228:692-705. doi: 
      10.1016/j.ijbiomac.2022.12.154. Epub 2022 Dec 22.